Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 19/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.73 |
| ▸ | MC4R | P32245 | 1/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.73 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.61 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21629465 | 0.94 | CFTR (0.88) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL2973385 | 0.89 | CFTR (0.80) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL397527 | 0.88 | CFTR (1.00) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL2976145 | 0.88 | CFTR (1.00) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL393603 | 0.87 | CFTR (1.00) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL396079 | 0.87 | CFTR (1.00) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL396270 | 0.87 | CFTR (0.80) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL397545 | 0.87 | CFTR (1.00) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL396475 | 0.86 | CFTR (0.76) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL396856 | 0.86 | CFTR (0.76) | CFTRADORA3ADRB3TBXA2RSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | claimed |
| US-20140187770-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-03 | — | — | US | claimed |
| US-20130331567-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-12 | — | — | US | claimed |
| EP-2502911-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-09-26 | — | — | EP | claimed |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | claimed |
| CN-107501099-B | Modulators of ATP-binding cassette transporters | 沃泰克斯药物股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10759721-B2 | Deuterated CFTR potentiators | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-10759721-B2 | Deuterated CFTR potentiators | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1773816-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187770-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 284/4885ADRB3 290/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 284/4885ADRB3 290/4885 |
| US-10759721-B2 | Deuterated CFTR potentiators | CFTR, SLC26A3, SLC26A4 | CFTR 1/4885ADORA3 600/4885ADRB3 356/4885 |
| US-20130331567-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 284/4885ADRB3 290/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | CFTR 1/4885ADORA3 491/4885ADRB3 324/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | CFTR 1/4885ADORA3 361/4885ADRB3 274/4885 |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 187/4885ADRB3 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.